JP2023512763A5 - - Google Patents
Info
- Publication number
- JP2023512763A5 JP2023512763A5 JP2022547697A JP2022547697A JP2023512763A5 JP 2023512763 A5 JP2023512763 A5 JP 2023512763A5 JP 2022547697 A JP2022547697 A JP 2022547697A JP 2022547697 A JP2022547697 A JP 2022547697A JP 2023512763 A5 JP2023512763 A5 JP 2023512763A5
- Authority
- JP
- Japan
- Prior art keywords
- item
- crystalline form
- anhydrous crystalline
- compound
- respect
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025093285A JP2025120268A (ja) | 2020-02-06 | 2025-06-04 | 眼疾患の処置のための組成物 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062971002P | 2020-02-06 | 2020-02-06 | |
| US62/971,002 | 2020-02-06 | ||
| US202063010212P | 2020-04-15 | 2020-04-15 | |
| US63/010,212 | 2020-04-15 | ||
| PCT/US2021/016414 WO2021158663A1 (en) | 2020-02-06 | 2021-02-03 | Compositions for treatment of ocular diseases |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025093285A Division JP2025120268A (ja) | 2020-02-06 | 2025-06-04 | 眼疾患の処置のための組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023512763A JP2023512763A (ja) | 2023-03-29 |
| JP2023512763A5 true JP2023512763A5 (cg-RX-API-DMAC10.html) | 2024-02-09 |
Family
ID=77200537
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022547697A Pending JP2023512763A (ja) | 2020-02-06 | 2021-02-03 | 眼疾患の処置のための組成物 |
| JP2025093285A Pending JP2025120268A (ja) | 2020-02-06 | 2025-06-04 | 眼疾患の処置のための組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025093285A Pending JP2025120268A (ja) | 2020-02-06 | 2025-06-04 | 眼疾患の処置のための組成物 |
Country Status (11)
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7664239B2 (ja) * | 2019-10-30 | 2025-04-17 | パフューズ セラピューティクス, インコーポレイテッド | エンドセリンレセプターアンタゴニストを使用する眼疾患の処置 |
| CA3168810A1 (en) | 2020-02-06 | 2021-08-12 | Perfuse Therapeutics, Inc. | Compositions for treatment of ocular diseases |
| BR112023022705A2 (pt) | 2021-04-30 | 2024-01-16 | Perfuse Therapeutics Inc | Composições farmacêuticas e sistemas de entrega intravítrea de fármacos para o tratamento de doenças oculares |
| CN117295520A (zh) * | 2021-04-30 | 2023-12-26 | 珀弗斯治疗股份有限公司 | 使用内皮素受体拮抗剂治疗眼部疾病 |
| WO2025137005A1 (en) * | 2023-12-20 | 2025-06-26 | Perfuse Therapeutics, Inc. | Methods of preparing drug delivery systems for the treatment of ocular diseases |
| AU2024405327A1 (en) * | 2023-12-20 | 2026-07-02 | Perfuse Therapeutics, Inc. | Methods of preparing drug delivery systems for the treatment of ocular diseases |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU4282793A (en) | 1992-04-10 | 1993-11-18 | State Of Oregon Acting By And Through The Oregon State Board Of Higher Education On Behalf Of The Oregon Health Sciences University | A microneedle for injection of ocular blood vessels |
| TW536540B (en) * | 1997-01-30 | 2003-06-11 | Bristol Myers Squibb Co | Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe |
| US6639082B2 (en) | 2000-10-17 | 2003-10-28 | Bristol-Myers Squibb Company | Methods for the preparation of biphenyl isoxazole sulfonamides |
| CZ20032350A3 (en) | 2001-02-02 | 2004-03-17 | Merck Patent Gmbh | PHARMACEUTICAL FORMULATION COMPRISING PYRAZOLO 4,3-d PYRIMIDINES AND ENDOTHELIN RECEPTOR ANTAGONISTS OR THIENOPYRIMIDINES AND ENDOTHELIN RECEPTOR ANTAGONISTS |
| US20030176356A1 (en) * | 2001-04-24 | 2003-09-18 | University Of North Texas Health Science Center | Endothelin antagonists and endothelin-converting enzyme inhibitors for the treatment of glaucoma |
| GB0122318D0 (en) | 2001-09-14 | 2001-11-07 | Novartis Ag | Organic compounds |
| US7927613B2 (en) * | 2002-02-15 | 2011-04-19 | University Of South Florida | Pharmaceutical co-crystal compositions |
| US8158152B2 (en) * | 2005-11-18 | 2012-04-17 | Scidose Llc | Lyophilization process and products obtained thereby |
| PL2424530T3 (pl) | 2009-04-30 | 2016-07-29 | Univ Midwestern | Sposób i kompozycja do leczenia cukrzycowej kwasicy ketonowej |
| US20110082151A1 (en) | 2009-06-12 | 2011-04-07 | Auspex Pharmaceuticals, Inc. | Sulfonylurea modulators of endothelin receptor |
| AR080888A1 (es) | 2010-04-12 | 2012-05-16 | R Tech Ueno Ltd | Uso de un derivado de acido graso para producir una composicion oftalmica |
| ES2813383T3 (es) | 2013-12-19 | 2021-03-23 | Tassos Georgiou | Composición de ácidos grasos omega 3 para tratar enfermedades que implican daños en el sistema nervioso |
| RU2016133980A (ru) * | 2014-01-23 | 2018-03-01 | Экебиа Терапьютикс, Инк. | Композиции и способы для лечения заболеваний глаз |
| ES2584534B1 (es) | 2015-03-27 | 2017-03-13 | Retinset, S.L. | Formulación tópica oftálmica de bosentan |
| JP2018522942A (ja) | 2015-05-29 | 2018-08-16 | エッジ セラピューティクス インコーポレイテッド | 視力障害を低減するための組成物及び方法 |
| JP6745594B2 (ja) * | 2015-11-26 | 2020-08-26 | 持田製薬株式会社 | ピラゾール誘導体の塩の結晶 |
| WO2017217967A1 (en) | 2016-06-13 | 2017-12-21 | Noveome Biotherapeutics, Inc. | Novel methods for delivering therapeutic agents to the eye via nasal passages |
| WO2018185516A1 (en) * | 2017-04-05 | 2018-10-11 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for treating cardiovascular toxicity induced by anti-cancer therapy |
| US11286274B2 (en) | 2017-06-19 | 2022-03-29 | Mitopower Llc | Nicotinamide riboside derivatives and their uses |
| US10905770B2 (en) | 2017-07-17 | 2021-02-02 | Macregen, Inc. | Topical delivery of therapeutic agents using cell-penetrating peptides for the treatment of age-related macular degeneration and other eye diseases |
| KR102771305B1 (ko) * | 2017-09-15 | 2025-02-24 | 모찌다 세이야쿠 가부시끼가이샤 | 테트라히드로나프틸우레아 유도체의 결정 |
| WO2019210194A1 (en) | 2018-04-26 | 2019-10-31 | Vitrisa Therapeutics, Inc. | Pegylated compositions for ocular use, and methods thereof |
| JP7664239B2 (ja) | 2019-10-30 | 2025-04-17 | パフューズ セラピューティクス, インコーポレイテッド | エンドセリンレセプターアンタゴニストを使用する眼疾患の処置 |
| CA3168810A1 (en) | 2020-02-06 | 2021-08-12 | Perfuse Therapeutics, Inc. | Compositions for treatment of ocular diseases |
-
2021
- 2021-02-03 CA CA3168810A patent/CA3168810A1/en active Pending
- 2021-02-03 EP EP21751181.5A patent/EP4100406A4/en active Pending
- 2021-02-03 CN CN202180013043.1A patent/CN115103842A/zh active Pending
- 2021-02-03 IL IL294873A patent/IL294873A/en unknown
- 2021-02-03 MX MX2022009677A patent/MX2022009677A/es unknown
- 2021-02-03 BR BR112022015579A patent/BR112022015579A2/pt unknown
- 2021-02-03 WO PCT/US2021/016414 patent/WO2021158663A1/en not_active Ceased
- 2021-02-03 AU AU2021217358A patent/AU2021217358A1/en active Pending
- 2021-02-03 JP JP2022547697A patent/JP2023512763A/ja active Pending
- 2021-02-03 KR KR1020227030697A patent/KR20220143685A/ko active Pending
-
2022
- 2022-08-02 US US17/879,627 patent/US11873279B2/en active Active
-
2023
- 2023-12-04 US US18/528,378 patent/US20240109876A1/en active Pending
-
2025
- 2025-06-04 JP JP2025093285A patent/JP2025120268A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10918656B2 (en) | Therapeutic agent for dry eye characterized by being applied to eye of dry eye patient wearing soft contact lens | |
| JP2009029828A (ja) | Rhoキナーゼ阻害剤とβ遮断薬からなる緑内障治療剤 | |
| EA016227B1 (ru) | Способ лечения офтальмологических неоваскулярных расстройств | |
| JP5875585B2 (ja) | 緑内障および高眼圧症の処置のためのアデノシンa1アゴニスト | |
| CN115103842A (zh) | 用于治疗眼部疾病的组合物 | |
| US8501708B2 (en) | Adenosine compounds and their use thereof | |
| JP2010514733A (ja) | 高眼圧症の治療のためのイソソルビドモノニトレート誘導体 | |
| WO2019124489A1 (ja) | セペタプロストとep2アゴニストとの組み合わせ医薬 | |
| JP2022520410A5 (cg-RX-API-DMAC10.html) | ||
| CN102933593A (zh) | 使用n6-环戊基腺苷(cpa)、cpa衍生物或其前药降低人眼内压的方法 | |
| US20240182428A1 (en) | Prodrug of celecoxib, preparation method therefor and application thereof | |
| WO2022034909A1 (ja) | セペタプロストを含有する医薬製剤 | |
| TW201309343A (zh) | 經改善親水性藥物之藥物移行性之水性組成物 | |
| US5055480A (en) | Topically active ocular gem-diacylthiadiazole sulfonamide carbonic anhydrase inhibitors | |
| CN111479567B (zh) | 包含FP激动剂和β-阻断剂的青光眼的治疗剂 | |
| JP2024516829A5 (cg-RX-API-DMAC10.html) | ||
| JP2012250947A (ja) | アデノシン誘導体とβ受容体遮断薬の組合せ剤 | |
| JP2012250953A (ja) | アデノシン誘導体とα2受容体作動薬の組合せ剤 | |
| TWI917308B (zh) | 歐米德尼培(Omidenepag)之組合 | |
| JP2012250950A (ja) | アデノシン誘導体とプロスタグランジン類の組合せ剤 | |
| TW202539693A (zh) | 用以使罹患青光眼或高眼壓症之患者於夜間睡眠時之眼壓下降之含有賽佩普斯特(Sepetaprost)之點眼液 | |
| JP2012250952A (ja) | アデノシン誘導体とRhoキナーゼ阻害剤の組合せ剤 | |
| JP2012250948A (ja) | アデノシン誘導体と炭酸脱水酵素阻害剤の組合せ剤 |